Eli Lilly a déclaré un bénéfice élevé et un dividende élevé, augmentant sa cote d'actions à un «Moderate Buy». Eli Lilly reported strong earnings and a high dividend, boosting its stock rating to a "Moderate Buy."

Eli Lilly and Company a déclaré un bénéfice élevé de 3,34 $ par action, dépassant les attentes, et a déclaré un dividende trimestriel de 1,50 $ par action. Eli Lilly and Company reported strong earnings of $3.34 per share, exceeding expectations, and declared a quarterly dividend of $1.50 per share. Plusieurs investisseurs institutionnels ont augmenté leurs participations dans Eli Lilly, dont North Star Asset Management Inc., qui a augmenté sa position de 2,0%, et Forum Financial Management LP, qui a augmenté sa participation de 3,2 %. Several institutional investors have increased their holdings in Eli Lilly, including North Star Asset Management Inc., which raised its position by 2.0%, and Forum Financial Management LP, which increased its stake by 3.2%. Le stock est coté un «Moderate Buy» avec un prix cible de 1 011,37 $. The stock is rated a "Moderate Buy" with a price target of $1,011.37.